About 604,000 results
New Novartis data in relapsing MS reinforce benefits of Kesimpta…
Novartis publishes new five-year efficacy data on Kesimpta® …
FDA approves Novartis Kesimpta® (ofatumumab), the first and …
AAN 2023: MS disability not worse for most on Kesimpta 5 years
AAN 2024: Long-term data support early Kesimpta start in …
Novartis Kesimpta® six-year efficacy data show substantial …
Novartis presents new five-year data on disability outcomes and …
FDA approves Novartis Kesimpta® (ofatumumab), the first and …
Kesimpta reduces relapses, brain lesions for up to 5 years: Study
Head-to-Head Comparison of Kesimpta vs Ocrevus Treatment in …